Souhaitez-vous accéder aux communiqués récents ?

RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early...

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of...

Calgarians are invited to join Operation Eyesight for an inspiring night at the movies at TELUS Spark’s Infinity Dome theatre on October 26.

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the...

New York, USA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Diabetic Retinopathy Market to Register Incremental Growth by 2032, Asserts DelveInsight | Leading Companies in the Market - Opthea, Regenxbio,...

Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities...

Vancouver, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The global brain-computer interface market size was USD 1,784.0 Million in 2021. Increasing attention in integrating brain-computer interface (BCI)...

Vancouver, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The global PVDF market size is expected to reach USD 1,851.09 Million at a steady CAGR of 6.6% in 2032 and register a revenue CAGR over the forecast...

Shenzhen, China, Sept. 28, 2023 (GLOBE NEWSWIRE) -- On 25th September 2023, Wanbo officially released the new products of the Professor X series. Continuing the exploration and breakthroughs in the...

Newark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 8 billion in 2022 global Osteosynthesis devices market will reach USD 15.73 billion in 2032. The senior...